Early virological failure in naive human immunodeficiency virus patients receiving saquinavir (soft gel capsule)-stavudine-zalcitabine (MIKADO trial) is not associated with mutations conferring viral resistance

Journal of Clinical Microbiology

Volumn 38, Issue 7, 2000, Pages 2726-2730

  Mouroux, M ^a   Yvon Groussin, A ^a   Peytavin, G ^b   Delaugerre, C ^a   Legrand, M ^a   Bossi, P ^a   Do, B ^a   Trylesinski, A ^c   Diquet, B ^a   Dohin, E ^c   Delfraissy, J F ^d   Katlama, C ^a   Calvez, V ^a   Abbed, A ^e   Auger, S ^e   Aquilina, C ^e   Bardot, P ^e   Benhamou, Y ^e   Benslama, L ^e   Bonhomme, M ^e   Costagliola, D ^e   Dumon, B ^e   Dupon, M ^e   Dussaix, E ^e   Ferre, V ^e   Fleury, H ^e   Gasnault, J ^e   Izopet, J ^e   Klein, E ^e   Lacoste, D ^e   Lecuyer, I ^e   Michaut, D ^e   Pellegrin, J L ^e   Pialoux, G ^e   Raffi, F ^e   Ragnaud, J M ^e   Raguin, G ^e   Vittecoq, D ^e   Khalifa, S ^e   Rannou, M T ^e   Sandre, A ^e   Mbadi, I ^e   more..

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b BICHAT HOSPITAL   (France)

^c ROCHE FRANCE   (France)

^d BICÊTRE HOSPITAL   (France)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

SAQUINAVIR; STAVUDINE; ZALCITABINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MECHANISM; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; PHENOTYPE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE; VIRUS LOAD; VIRUS MUTATION; VIRUS RESISTANCE;

HUMAN IMMUNODEFICIENCY VIRUS; RNA VIRUSES;

EID: 0033929132     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/jcm.38.7.2726-2730.2000     Document Type: Article

References (20)

1. Boucher, C. A., W. Keulen, T. van Bommel, M. Nijhuis, D. de Jong, M. D. de Jong, P. Schipper, and N. K. Back. 1996. Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses gencrated from patient sera tested in a cell-killing assay. Antimicrob. Agents Chemother. 40:2404-2409.
2. Burger, D. M., R. M. W. Hoetelmans, P. W. H. Hugen, J. W. Mulder, P. L. Meenhorst, P. P. Koopmans, K. Brinkman, M. Keuter, W. Dolmans, and Y. A. Hekster. 1998. Low plasma concentrations of indinavir are related to virological treatment failure in HIV-1-infected patients on indinavir-containing triple therapy. Antivir. Ther. 3:215-220.
3. Committee for Proprietary Medicinal Products (CPMP) 723/98 and European Agency for Evaluation of Medicinal Products (EMEA) H/C/178. 1998. Fortovase. European Public Assessment Report.
4. Craig, C., E. Race, J. Sheldon, L. Whittaker, S. Gilbert, A. Moffatt, J. Rose, S. Dissanayeke, G. W. Chirn, I. B. Duncan, and N. Cammack. 1998. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS 12:1611-1618.
5. Descamps, D., P. Flandre, V. Calvez, G. Peytavin, V. Meiffredy, G. Collin, C. Delaugerre, S. Robert-Delmas, B. Bazin, J. P. Aboulker, G. Pialoux, F. Raffi, and F. Brun-Vezinet. 2000. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. JAMA 283:205-211.
6. Drusano, G. L., J. A. Bilello, D. S. Stein, M. Nessly, A. Meibohm, E. A. Emini, P. Deutsch, J. Condra, J. Chodakewitz, and D. J. Holder. 1998. Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables. J. Infect. Dis. 178:360-367.
7. Drusano, G. L., and D. S. Stein. 1998. Mathematical modeling of the interrelationship of CD4 lymphocyte count and viral load changes induced by the protease inhibitor indinavir. Antimicrob. Agents Chemother. 42:358-361.
8. Havlir, D. V., I. C. Marschner, M. S. Hirsch, A. C. Collier, P. Tebas, R. L. Bassett, J. P. Ioannidis, M. K. Holohan, R. Leavitt, G. Boone, and D. D. Richman. 1998. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N. Engl. J. Med. 339:1261-1268.
9. Havlir, D. V., N. S. Hellman, C. J. Petropoulos, J. M. Whitcomb, A. C. Collier, M. S. Hirsch, P. Tebas, J. P. Sommadossi, and D. D. Richman. 2000. Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. JAMA 283:229-234.
10. Kellam, P., and B. A. Larder. 1994. Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob. Agents Chemother. 38:23-30.
11. Maschera, B., E. Furfine, and E. D. Blair. 1995. Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. J. Virol. 69:5431-5436.
12. Mocroft, A., M. J. Gill, W. Davidson, and A. N. Phillips. 1998. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS 12:2161-2167.
13. Myers, G., S. F. Josephs, A. B. Rabson, and T. F. Smith. 1987. Clade B consensus human retroviruses and AIDS. Los Alamos National Laboratory, Los Alamos, N. Mex.
14. Noble, S., and D. Faulds. 1996. Saquinavir. A review of its pharmacology and clinical potential in the management of HIV infection. Drugs 52:93-112.
15. Perry, C. M., and S. Noble. 1998. Saquinavir soft-gel capsule formulation. A review of its use in patients with HIV infection. Drugs 55:461-486.
16. Pialoux, G., F. Raffi, F. Brun-Vezinet, V. Meiffredy, P. Flandre, J. A. Gastaut, P. Dellamonica, P. Yeni, J. F. Delfraissy, and J. P. Aboulker. 1998. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilege (Agence Nationale de Recherches sur le SIDA 072) Study Team. N. Engl. J. Med. 339:1269-1276.
17. Raboud, J. M., J. S. Montaner, B. Conway, S. Rae, P. Reiss, S. Vella, D. Cooper, J. Lange, M. Harris, M. A. Wainberg, P. Robinson, M. Myers, and D. Hall. 1998. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS 12:1619-1624.
18. Schapiro, J. M., J. Lawrence, R. Speck, M. A. Winters, B. Efron, R. W. Coombs, A. C. Collier, and T. C. Merigan. 1999. Resistance mutations to zidovudine and saquinavir in patients receiving zidovudine plus saquinavir or zidovudine and zalcitabine plus saquinavir in AIDS clinical trials group 229. J. Infect. Dis. 179:249-253.
19. Schinazi, R., B. Larder, and J. Mellors. 1999. Mutations in retroviral genes associated with drug resistance. Int. Antivir. News 7:46-69.
20. Schuurman, R., M. Nijhuis, R. van Leeuwen, P. Schipper, D. de Jong, P. Collis, S. A. Danner, J. Mulder, C. Loveday, C. Christopherson, et al. 1995. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J. Infect. Dis. 171:1411-119.